Go Deep
Hemab Therapeutics Holdings, Inc.
Hemab Therapeutics Holdings, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,201 | -6.9 | 3.06 | 0.00 | 2,837.96 |
| Oct 2026 | 20,181 | -6.9 | 3.08 | 0.00 | 2,842.73 |
| Oct 2026 | 19,816 | -7.5 | 3.34 | 0.00 | 3,088.13 |
| Oct 2026 | 20,163 | -6.9 | 3.09 | 0.00 | 2,848.08 |
| Oct 2026 | 19,876 | -7.4 | 3.30 | 0.00 | 3,042.66 |
| Oct 2026 | 19,581 | -7.9 | 3.51 | 0.00 | 3,239.88 |
| Oct 2026 | 19,415 | -8.2 | 3.63 | 0.00 | 3,342.53 |
| Oct 2026 | 19,490 | -8.0 | 3.58 | 0.00 | 3,286.22 |
| Oct 2026 | 19,549 | -7.9 | 3.54 | 0.00 | 3,260.51 |
Hemab Therapeutics Holdings, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -24,150,000.0 | -22,687,000.0 | -12,209,000.0 | -15,306,000.0 |
| EPS | -0.8 | -0.5 | -0.4 | -0.6 |
Hemab Therapeutics Holdings, Inc. Revenue & Profit: Last 2 Years
| Line Item | Dec 2025 | Dec 2024 |
|---|---|---|
| Revenue | 0.0 | 0.0 |
| Net Profit | -63,913,000.0 | -48,707,000.0 |
| EPS | -2.3 | -1.8 |
Hemab Therapeutics Holdings, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 |
|---|---|---|
| Total Assets | 194,783,000.0 | 96,278,000.0 |
| Total Liabilities | 371,418,000.0 | 211,551,000.0 |
| Total Equity | -176,635,000.0 | -115,273,000.0 |
Owes vs Owns
Hemab Therapeutics Holdings, Inc. owed $0.03 for every $1 it owned in Jun 2026, down from $2.20 in Dec 2024.
| Period | Jun 2026 | Dec 2025 | Dec 2024 |
|---|---|---|---|
| Owes vs Owns | 0.03× | 1.91× | 2.20× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Hemab Therapeutics Holdings, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 95.2%Receivables 1.3%Fixed assets (tangible) 0.9%Other assets 2.6%
How it's funded — Dec 2025
Payables 1.5%Other liabilities 98.1%
| Line Item | Dec 2025 | Dec 2024 |
|---|---|---|
| Assets | ||
| Cash & short-term investments | 185.5 | 88.3 |
| Receivables | 2.6 | 1.6 |
| Inventory | 0.0 | 0.0 |
| Fixed assets (tangible) | 1.7 | 2.6 |
| Intangible assets | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 |
| Other assets | 5.0 | 3.8 |
| Liabilities & equity | ||
| Short-term debt | 0.6 | 0.7 |
| Long-term debt | 0.6 | 1.1 |
| Payables | 5.7 | 3.2 |
| Other liabilities | 364.5 | 206.7 |
| Shareholders' equity | -176.6 | -115.3 |
| Net tangible assets | -176.6 | -115.3 |
Hemab Therapeutics Holdings, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 |
|---|---|---|
| Operating Activities | -61,475,000.0 | -45,592,000.0 |
| Investing Activities | -81,482,000.0 | 61,903,000.0 |
| Financing Activities | 156,301,000.0 | -100,000.0 |